Subunit selective NMDA receptor potentiators for the treatment of neurological conditions

A compound having the following formula:

• wherein
• X is, independently, N or C bonded to H or a substituent, J, with the proviso that no more than one of X are N;
• Y is O;
• R1 and R2 are independently selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and hydroxy,
• R1 and R2 can optionally join to form a C3-10 heterocyclic moiety, which heterocyclic moiety can optionally include a second heteroatom selected from O, S, and N,
• z is an integer from 0 to 3,
• and
• J is a non-hydrogen substituent selected from the group consisting of halo (—F, —Cl, —Br, —I), amino (NR1R2), OR1, SR1, —R1, —CF3, —CN, —C2R1, —SO2CH3, —C(═O)NR1R2—NR′C(═O)R1, —C(═O)R1, —C(═O)OR1, —(CH2)qOR1, —OC(═O)R1, —OC(═O)NR1R2, —NR1(C═Y)—NR1R2, —NR1(C═Y)—OH, —NR1(C═Y)—SH, sulfonyl, sulfinyl, phosphoryl, and azo,
• wherein a substituted alkyl, substituted alkenyl, substituted aryl, or substituted heteroaryl is alkyl, alkenyl, aryl, or heteroaryl substituted with one or more substituent, wherein a substituent is fluoro, chloro, bromo, iodo, hydroxy, heterocyclic, heteroaryl, carboxy, alkoxy, NH2, N(alkyl)2, NH(alkyl), alkoxycarbonyl, —N(H or alkyl)C(O)(H or alkyl), —N(H or alkyl)C(O)N(H or alkyl)2, —N(H or alkyl)C(O)O(H or alkyl), —OC(O)N(H or alkyl)2, —S(O)n—(H or alkyl), —C(O)—N(H or alkyl)2, cyano, alkenyl, cycloalkyl, acyl, hydroxyalkyl, heterocyclic, heteroaryl, aryl, aminoalkyl, oxo, carboxyalkyl, —C(O)—NH2, —C(O)—N(H)O(H or alkyl), —S(O)2—NH2, —S(O)n—N(H or alkyl)2 and/or —S(O)2—N(H or alkyl)2
• wherein the dashed line is an optional double bond,
• and pharmaceutically acceptable salts, or esters thereof.